|Bid||100.00 x 800|
|Ask||125.00 x 800|
|Day's Range||103.23 - 105.29|
|52 Week Range||74.31 - 128.94|
|Beta (5Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2020 - Mar 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||122.22|
A federal has denied an injunction motion from Sandoz and RareGen, the companies selling a generic form of a drug that United Therapeutics had under patent until early 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
United Therapeutics Corp.’s (NASDAQ: UTHR) trial of one of its cancer therapies in small cell lung cancer did not achieve its goals, the company announced Monday. The Silver Spring company conducted a trial, called a DISTINCT study, of Unituxin in patients with some forms of small cell lung cancer, but said Monday that the therapy did not extend the overall survival of those patients. Unituxin, or dinutuximab, first received approval from the Food and Drug Administration in March 2015 to treat pediatric neuroblastoma, a high-risk cancer that mostly occurs in children under 5 and affects the adrenal glands.
United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin® (dinutuximab) Injection added to irinotecan compared to irinotecan or topotecan alone in patients with relapsed or refractory small cell lung cancer (SCLC). The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone. The safety profile of dinutuximab in DISTINCT was consistent with prior studies and the current Unituxin product label.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Today we will run through one way of estimating the intrinsic value of United Therapeutics Corporation (NASDAQ:UTHR...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
United Therapeutics Corporation (NASDAQ: UTHR ) may face stiffening competition from generic entrants, which could meaningfully increase pricing pressure and shrink its market share, according to Bank ...
Zacks.com featured highlights include: Plexus, Costamare, United Therapeutics, Intel and First American Financial
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.63% and 19.94%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 30, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, ...